Global Dermatology Drugs Market 2017-2023: Introduction to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
372
Global Dermatology Drugs Market 2017-2023: Introduction to Dermatology, Including Disease Epidemiology, Symptoms, Etiology, Pathophysiology, Co-Morbidities and Complications

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis" report has been added to Research and Markets' offering.

The report Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient's quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence. There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel. Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need. Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change. In depth, this report provides the following:

  • Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company's pipeline portfolio and total revenues.

Scope:

  • Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the largest growth in market share?
  • Which companies rely heavily on revenue derived from antibacterial drugs?
  • How will the market respond to recent approvals?
  • Will generics and biosimilars have a significant impact on the market over the forecast period?
  • What class of drugs dominate the market?
  • What molecular targets are most popular in the pipeline?
  • What are the commercial prospects for the most promising late-stage products?

Key Topics Covered:

1 Table of Contents 2 Introduction 2.1 Therapy Area Introduction 2.2 Symptoms 2.3 Etiology and Pathophysiology 2.3.1 Atopic Dermatitis 2.3.2 Acne Vulgaris 2.3.3 Psoriasis 2.4 Co-morbidities and Complications 2.5 Diagnosis, Scales and Grading 2.5.1 Atopic Dermatitis 2.5.2 Acne Vulgaris 2.5.3 Psoriasis 2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 2.6.1 Atopic Dermatitis 2.6.2 Acne Vulgaris 2.6.3 Psoriasis 2.7 Treatment 2.7.1 Topical Corticosteroids 2.7.2 Calcineurin Inhibitors 2.7.3 Retinoids 2.7.4 Systemic Immunosuppressive Agents 2.7.5 Biologics 2.7.6 Antihistamines 2.7.7 Hormonal Therapy 2.7.8 Moisturizers 3 Key Marketed Products 3.1 Overview 3.2 Humira (adalimumab) - AbbVie 3.3 Remicade (infliximab) - Johnson & Johnson 3.4 Enbrel (etanercept) - Amgen 3.5 Stelara (ustekinumab) - Johnson & Johnson 3.6 Neoral (cyclosporine) - Novartis 3.7 Protopic (tacrolimus) - Astellas Pharma 3.8 Cosentyx (Secukinumab) - Novartis 3.9 Dupixent (dupilumab) Sanofi and Regeneron 3.10 Taltz (ixekizumab) - Eli Lilly 3.11 Eucrisa (crisaborole) - Pfizer 3.12 Siliq (Brodalumab) - Valeant Pharmaceuticals 3.13 Elidel (pimecrolimus) 3.14 Elocon (mometasone furoate) 3.15 Differin (adapalene) 3.16 Metolate (methotrexate) 3.17 Clobex (clobetasol propionate) 3.18 Conclusion 4 Pipeline Landscape Assessment 4.1 Overview 4.2 Molecule Types in the Pipeline 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 4.4.5 Assessment of Key Pipeline Products 4.5 Conclusion 5 Multi-scenario Market Forecast to 2023 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target 5.3.1 Tumor Necrosis Factor-Alpha 5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 5.3.3 Calcineurin 5.3.4 Glucocorticoid Receptors 5.3.5 Phosphodiesterase 6 Company Analysis and Positioning 6.1 Revenue and Market Share Analysis by Company 6.1.1 Novartis - Will Revenue from Cosentyx Continue to Increase in the Forecast Period? 6.1.2 AbbVie - Will Humira's Patent Expiry Lead to Loss of Market Leadership? 6.1.3 Johnson & Johnson - Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade 6.1.4 Sanofi - High Revenue Growth from Dupixent Will See Sanofi's Revenue from the Dermatology Therapy Area Increase 6.1.5 Pfizer - Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area 6.1.6 Celgene - Otezla Expected to Achieve Blockbuster Status in the Therapy Area 6.2 Company Landscape 6.3 Marketed and Pipeline Portfolio Analysis 7 Strategic Consolidations 7.1 Licensing Deals 7.1.1 Deals by Region, Year and Value 7.1.2 Deals by Stage of Development and Value 7.1.3 Deals by Molecule Type, Mechanism of Action and Value 7.1.4 Figures for Licensing Deals Valued Above $100m 7.2 Co-development Deals 7.2.1 Deals by Region, Year and Value 7.2.2 Deals by Stage of Development and Value 7.2.3 Deals by Molecule Type, Mechanism of Action and Value 7.2.4 Figures for Co-development Deals Valued Above $100m 8 Appendix

Companies Mentioned

  • AbbVie
  • Amgen
  • Astellas Pharma
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Sanofi and Regeneron
  • Valeant Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/2hm9zm/global

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Immune Disorders Drugs, Immune Disorders Drugs, Dermatological Drugs , Dermatological Drugs , Psoriasis Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 26

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 183

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 123

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 31

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading

Top 5 Most Recently Viewed Articles

Delicious New Dips by Dean's Perfect for Every Snack Lovers

Updated Category News Views 536

Dean's Dip Launches Five Exciting New Flavors Dean's Dip, a well-loved name in the dairy dip sector, is thrilled to introduce its latest flavors, catering to snack aficionados everywhere. In addition to its classic offerings, the brand is now adding two delightful new dips — Creamy Dill and Jalapeño Popper. But that's not all! A fresh sub-line of dips, the Cantina...

Continue Reading
Bavarian Nordic Secures $63 Million for Vaccine Manufacturing

Updated Category News Views 102

Bavarian Nordic Secures New Contract with U.S. Government Bavarian Nordic A/S (Copenhagen: BAVA) has announced an important contract with the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). This order, worth USD 63 million, will enhance the nation's stockpile of smallpox/mpox vaccines and pave the way for producing more freeze-dried doses...

Continue Reading
NewtekOne, Inc. Declares Impressive Quarterly Dividend Update

Updated Category News Views 158

NewtekOne, Inc. Announces Quarterly Dividend Declaration NewtekOne, Inc. (NASDAQ: NEWT) has recently made an exciting announcement for its shareholders. The Board of Directors has declared a quarterly cash dividend amounting to $0.19 per share, which is a testament to the company's ongoing commitment to enhancing shareholder value. As the company gears up for this...

Continue Reading
New Clean Freak Car Wash Location Welcomes Local Community

Updated Category News Views 516

Exciting New Location of Clean Freak Car Wash Clean Freak Car Wash, an innovative company supported by Circle K, is thrilled to announce the grand opening of its latest location. This highly anticipated launch is set to bring exceptional car wash services, designed to provide customers with a refreshing and satisfying experience. Commitment to Quality and Eco-Friendly...

Continue Reading
Bernie Sanders Calls for Action Against Wealth Inequality Surge

Updated Category News Views 200

Bernie Sanders Raises Concerns Over Wealth Disparity Sen. Bernie Sanders has openly criticized the increasing wealth inequality in the country, highlighting the significant gains of a select group of billionaires. His latest remarks reflect deep concern for the financial struggles faced by millions of Americans. Wealth of Billionaires on the Rise In a striking statement,...

Continue Reading